Esra ERDEMLİ, Meral TEKELİOĞLU, Sibel SERİN

Osteoporoza yeni çözüm

Yaşlı populasyon arttıkça, osteoporoz riski altındaki insan sayısı da artmaktadır. Kemik geri emilimini engelleyen ilaçlar bulunmasına rağmen, osteoporoz tedavisinde asıl ihtiyaç duyulan tedavi, anabolik ajanlarla uygulanandır. Bizim çalımamızda; kolesterol biyosentezinde ilk basamağı kontrol eden 3-hidroksi-3-metilglutaril Koenzim A redüktazı inhibe ederek etki eden simvastatinin kemik oluşumunu uyardığı in vivo olarak sıçanlarda gösterilmiştir. Bu çalışmanın amacı ; kontrol ve simvastatin uygulandıktan sonra 7.,14. ve 21. günlerde incelenmek üzere dört gruba ayrılan sıçanlarda, normal kemik dokusundaki değişiklikleri değerlendirmektir. Sağlıklı bir hayvan modelinde izlenen değişiklikler; kılcal damar gelişimiyle beraber, kemik öncü hücrelerinde çoğalma ve farklanmada artış ve yeni osteoid doku oluşumudur.

New solution to osteoporosis

The number of people under the risk of osteoporosis is growing as the elderly population increases. Although there is such of drugs that inhibit bone resorption, the main therapy needed is an anabolic agent for the treatment of osteoporosis.In our study; inhibitor of the enzyme 3- hydroxy-3- methylglutaryl Coenzyme A (HMG-CoA) reductase, simvastatin, which controls the first step in the biosynthesis of cholesterol, has been shown to stimulate bone formation in rats in vivo. The aim of this study is to investigate the changes in normal bone tissue in rats that is grouped to four as a control and 7., 14., 21. day groups following simvastatin injection. The observed effects of the bone in a healty animal model included advencement of the blood supply, acceleration of the proliferation and differantiation of osteoprogenitor cells and formation of osteoid tissue.

PDF

___

1- Garret R, Mundy G, Harris S, Chan J, Chan J ve ark. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286:1946-49
2- Meunier P. Prevention of hip fractures by correcting calcium and vitamin D insufficiencies in el¬derly people. Scand J Rheumatol Supply 1996;103:75-8
3- Nordin BE, Morris HA. Osteoporosis and vitamin D. J Cell Biochem 1992;49(1): 19-25
4- Lopez FJ. New approaches to the treatment of oste- oporosis. Current opinion in chemical biology 2000;4(4): 383-93
5- Watanabe S, Takeuchi Y, Nakano T. Effects of 1-Ye- ar Treatment with Fluvastatin or Pravastatin on Bone. The American Journal of Medicine 2001:110; 584-587
6- Edna B. Laboratory Methods in Histotechnology 1992:71-75
7- Reynolds TM, Marshall PÖ. Hip fracture patients may be vitamin B6 deficient. Controlled study of serum pyridoxal-5'-phosphate. Acta Orthop Scand 1992: 63(6);635-8
8- Kaneki M, Mizuno Y, Hosoi T, Inoue S, Hoshino S ve ark. Serum concentration of vitamin K in el¬derly women with involutional osteoporosis. Nippon Ronen Igakkai Zasshi 1995:32(3);195-200
9- Schmuck A, Ravel A, Coudray C, Alary J, Franco A ve ark. Antioxidant vitamins in hospitalized el¬derly patients: analysed dietary intakes and bi¬ochemical status. Eur J Clin Nutr 1996- 50(7)-473-8
10- Reid IR. Therapy of osteoporosis: calcium, vitamin D, and exercise. Am J Med Sci 1996: 312(6)-278-286
11- Michaelsson K, Holberg I, Malimin H/ Sörensen S, Wolk A ve ark. Diet and hip fracture risk: a ca¬se-control study. Study Group of the Multiple Risk Survey on Swedish Women for Eating As¬sessment. IntJ Epidemiol 1995: 24(4); 771-82
12- Bonjour JP, Schurch MA, Rizzoli R. Nutritional as- pects of hip fractures. Bone 1996:18(3)- 139-144
13- L.evadot J, Murasawa S/ Kureishi Y, Uchida S, Ma- suda H ve ark. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. Journal of clinical investigation 2001: 108(3); 399-405
14- Garret IR, Mundy CR, Gutierrez G. Statins and bo- ne formation. Current Pharmaceutical design 2001: 7(8);715-36